Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that the Data and Safety Monitoring Board recommended the Company proceed to the eighth cohort of the Phase 1 dose escalation ReSPECT™ trial, which is evaluating the Company's lead investigational drug, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial

AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6 th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021.

Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference

AUSTIN, Texas, June 09, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.

Plus Therapeutics to Participate in BIO Digital Conference

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) went from $2.60 to $2.84 (up 9.23%) pre-market. This is why it happened.

PSTV Stock: From $2.60 To $2.84 (9.23% Increase) Pre-Market Explanation

– Agreements are a major step for ongoing clinical trials and future commercial drug supply – Agreements are a major step for ongoing clinical trials and future commercial drug supply

Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript

Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET

Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, announced that the Company will report first quarter 2021 financial results on Thursday, April 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 2021

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 40% pre-market. This is why it happened.

PSTV Stock Price Increases Over 40% Pre-Market: Why It Happened

Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets

Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization

AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences.

Plus Therapeutics to Participate in Upcoming Virtual Conferences

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript

– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –

Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 22, 2021

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO CEO & Investor Digital Conference being held February 16-18, 2021.

Plus Therapeutics to Participate in BIO CEO & Investor Digital Conference

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced completion of the sixth dosing cohort in the ReSPECT™ Phase 1 clinical trial evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

Plus Therapeutics Completes Sixth Dosing Cohort in ReSPECT™ Glioblastoma Trial

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET.

Plus Therapeutics to Present at 13th Annual LD Micro Main Event Conference

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company's lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM).

Plus Therapeutics Expands ReSPECT™ Clinical Trial to MD Anderson Cancer Center

Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy

Plus Therapeutics Announces Positive Interim Data from ReSPECT™ Phase 1 Clinical Trial in Recurrent Glioblastoma

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today announced that Company management has been invited to participate in two upcoming virtual investor conferences:

Plus Therapeutics to Participate in Upcoming November Investor Conferences

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data

Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update

Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression

Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT™ Glioblastoma Trial

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2020 Results - Earnings Call Transcript

– Receive d FDA O rphan D rug and Fast Track designations for novel glioblastoma radiotherapy –

Plus Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

AUSTIN, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to participate in the Cancer Innovation Summit. The meeting, which is hosted by Health Tech Austin, is being held virtually on Thursday, October 22 from 12.00 to 3.00 p.m. EDT.

News for Plus Therapeutics Inc Stock (PSTV)